

ABSTRACT

The present disclosure provides a stereoisomer, deuterated derivative or stereoisomeric deuterated derivative of a compound represented by formula (I), or a pharmaceutically acceptable salt and solvate thereof, which can be used as a PLK1 inhibitor, wherein R¹ and R² are as described herein. Further provided are a pharmaceutical composition comprising the stereoisomer, deuterated derivative or stereoisomeric deuterated derivative, or the pharmaceutically acceptable salt and solvate, and a use in the treatment of diseases and symptoms caused by PLK1 activity disorders and/or PLK1-related diseases and symptoms, such as cancer.

